

Marta Sobas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7555058/publications.pdf>

Version: 2024-02-01

24
papers

153
citations

1163117

8
h-index

1281871

11
g-index

25
all docs

25
docs citations

25
times ranked

426
citing authors

#	ARTICLE	IF	CITATIONS
1	Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group. <i>Leukemia and Lymphoma</i> , 2021, 62, 2928-2938.	1.3	21
2	Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide”an International Collaborative Study. <i>Leukemia</i> , 2020, 34, 2333-2341.	7.2	20
3	PLZF-RAR±, NPM1-RAR±, and Other Acute Promyelocytic Leukemia Variants: The PETHEMA Registry Experience and Systematic Literature Review. <i>Cancers</i> , 2020, 12, 1313.	3.7	20
4	Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy. <i>Leukemia and Lymphoma</i> , 2019, 60, 1146-1155.	1.3	12
5	The risk of thrombosis in essential thrombocythemia is associated with the type of <i>CALR</i> mutation: A multicentre collaborative study. <i>European Journal of Haematology</i> , 2021, 106, 371-379.	2.2	12
6	Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs. <i>Blood Advances</i> , 2022, 6, 5171-5183.	5.2	12
7	Allogeneic hematopoietic stem cell transplantation with fludarabine, busulfan, and thiotepa conditioning is associated with favorable outcomes in myelofibrosis. <i>Bone Marrow Transplantation</i> , 2020, 55, 147-156.	2.4	10
8	An analysis of the impact of CD56 expression in <i>de novo</i> acute promyelocytic leukemia patients treated with upfront all-trans retinoic acid and anthracycline-based regimens. <i>Leukemia and Lymphoma</i> , 2019, 60, 1030-1035.	1.3	9
9	Primary cutaneous indolent B-cell lymphomas – a retrospective multicenter analysis and a review of literature. <i>Acta Oncologica</i> , 2021, 60, 1361-1368.	1.8	7
10	Characteristics and outcome of adult patients with acute promyelocytic leukemia and increased body mass index treated with the PETHEMA Protocols. <i>European Journal of Haematology</i> , 2020, 104, 162-169.	2.2	6
11	Profound Nanoscale Structural and Biomechanical Changes in DNA Helix upon Treatment with Anthracycline Drugs. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4142.	4.1	6
12	Immune Thrombocytopenia and JAK2V617F Positive Essential Thrombocythemia: Literature Review and Case Report. <i>Case Reports in Hematology</i> , 2017, 2017, 1-4.	0.4	5
13	Primary Immune Thrombocytopenia and Essential Thrombocythemia: So Different and yet Somehow Similar”Cases Series and a Review of the Literature. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10918.	4.1	4
14	Risk-adjusted safety analysis of pacritinib (PAC) in patients (pts) with myelofibrosis (MF).. <i>Journal of Clinical Oncology</i> , 2022, 40, 7058-7058.	1.6	3
15	Real life outcomes of patients aged ≥75 years old with acute promyelocytic leukemia: experience of the PETHEMA registry. <i>Leukemia and Lymphoma</i> , 2019, 60, 2720-2732.	1.3	2
16	Impact of Sars-Cov-2 Infection in Acute Myeloid Leukemia Patients: Experience of the Pethema Registry. <i>Blood</i> , 2020, 136, 7-8.	1.4	2
17	Early induction intensification with cladribine, cytarabine, and mitoxantrone (CLAM) in AML patients treated with the DAC induction regimen: a prospective, non-randomized, phase II study of the Polish Adult Leukemia Group (PALG). <i>Leukemia and Lymphoma</i> , 2020, 61, 588-603.	1.3	1
18	Cladribine, Cytarabine and Mitoxantrone As Treatment Intensification for Patients with Acute Myeloid Leukemia with the Excess of Bone Marrow Blasts on Day 14 of the First Induction. Prospective, Multicenter Study by the Polish Adult Leukemia Group (PALG). <i>Blood</i> , 2016, 128, 213-213.	1.4	1

#	ARTICLE	IF	CITATIONS
19	Characteristics and Outcome of Older Patients with Acute Promyelocytic Leukemia Front-Line Treated with or without Arsenic Trioxide – an International Collaborative Study. <i>Blood</i> , 2018, 132, 80-80.	1.4	0
20	Analysis of Predictive Factors for Early Response to Ruxolitinib in 266 Patients with Myelofibrosis from the Polish Adult Leukemia Group (PALG) Registry. <i>Blood</i> , 2019, 134, 4180-4180.	1.4	0
21	Characteristics and Outcomes of Patients with Lymphoma Who Developed Therapy-Related Acute Myeloid Leukemia or Myelodysplastic Syndrome - a Retrospective Analysis of the Polish Adult Leukemia Group. <i>Blood</i> , 2019, 134, 5422-5422.	1.4	0
22	The Prognostic Value of Early Measurable Residual Disease Assessment in Patients with Acute Myeloid Leukemia Treated with Intensive Chemotherapy - Preliminary Results of Polish Adult Leukemia Group PALG-AML1/2016 Study. <i>Blood</i> , 2021, 138, 3453-3453.	1.4	0
23	Impact of Gender on Molecular AML Subclasses - a Harmony Alliance Study. <i>Blood</i> , 2021, 138, 3438-3438.	1.4	0
24	A Polish Acute Leukemia Group Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in Acute Myeloid Leukemia (AML) Patients ≥ 60 Years Old (PALG-AML1/2016). <i>Blood</i> , 2020, 136, 3-4.	1.4	0